Renal allograft rejection 46

First clinical trials with OKT3 (therapy of renal allograft rejection)... [Pg.1179]

Bohmig GA, Exner M, Watschinger B, Regele H. Acute humoral renal allograft rejection. Curr Opin Urol 2002 12 95-99. [Pg.150]

Joosten SA, Sijpkens YW, van Kooten C, Paul LC. Chronic renal allograft rejection pathophysiologic considerations. Kidney Int 2005 68 1-13. [Pg.151]

Panzer U, Reinking RR, Steinmetz OM, et al. CXCR3 and CCR5 positive T-cell recruitment in acute human renal allograft rejection. Transplantation 2004 78 1341-1350. [Pg.153]

Hauser I A, Spiegler S, Kiss E, et al. Prediction of acute renal allograft rejection by urinary monokine induced by IFN-gamma (MIG). J Am Soc Nephrol 2005 16 1849-1858. [Pg.153]

Obstructive uropathy Pre- and post-renal azotemia Renal allograft rejection shock/hypotension Patients recovering from surgery (vascular) ... [Pg.53]

Renal allograft rejection Treatment of acute allograft rejection in renal transplant patients. [Pg.1976]

Renal allograft rejection, acute 5 mg/day for 10 to 14 days. Begin treatment once acute renal rejection is diagnosed. [Pg.1976]

Sirolimus (Rapamune) is structurally related to tacrolimus. It is approved for use as an adjunctive agent in combination with cyclosporine for prevention of acute renal allograft rejection. It blocks IL-2-dependent T-cell proliferation by inhibiting a cytoplasmic serine-threonine kinase. This mechanism of action is different from those of tacrolimus and cyclosporine. This allows sirolimus to augment the immunosuppressive effects of these drugs. [Pg.660]

Adjunct in prevention of renal allograft rejection PO, IV 2-5 mg/kg/day on day of transplant, then 1-3 mg/kg/day as maintenance dose. [Pg.108]

H. Other considerations Daclizumab has been designated an orphan product for use in the prevention of acute renal allograft rejection. [Pg.292]

Tacrolimus (previously known as FK506) is a macrolide antibiotic with immunosuppressive properties very similar to cyclosporin. It is more potent than cyclosporin but the side effects are similar. Tacrolimus is a very active immunosuppressive drug both in the prevention and treatment of liver and renal allograft rejection. It is especially valuable for small bowel transplantation. [Pg.253]

Thistlethwaite, J.R., Cosimi, A.B., Delmonico, F.L., et al. (1984). Evolving use of OKT3 monoclonal antibody for treatment of renal allograft rejection. Transplantation, 38, 695-701. [Pg.146]

Indications Management of renal allograft rejection Adjunct to other immunosuppressive therapy to delay the onset of the first rejection episode... [Pg.5]

Indication Treatment of acute renal allograft rejection in combination with other immunosuppressants... [Pg.6]

Indications Prophylaxis of acute renal allograft rejection when used as part of an immunosuppressive regimen that includes steroids and cyclosporine... [Pg.21]

Mycophenolic acid (MPA) was isolated from cultures of Penicillium spp. in 1896 and was purified in 1913. Initially the compound was studied for its antifungal and antibacterial effects and later for its antitumor effects. Many years later, its immunosuppressive activities were recognized and after further developmental work, an ester prodrug mycophenolate mofetil was developed, which was approved by the United States Food and Drug Administration for the prevention of acute renal allograft rejection in 1995 and for heart transplant recipients in 1998. Mycophenolate mofetil is a cytotoxic agent now used for immunosuppressive therapy and is the mofetil ester of MPA, which is the active immunosuppressive agent. [Pg.96]

Boratynska M, Banasik M, Patrzalek D, Klinger M. 2006. Conversion from cyclosporine-based immunosuppression to tacrolimus/mycophenolate mofetil in patients with refractory and ongoing acute renal allograft rejection. Ann Transplant. 11 51-56. [Pg.103]

Cosimi AB, Burton RD, Colvin RB, Goldstein G. 1981. Treatment of cute renal allograft rejection with OKT3 monoclonal antibody. Transplantation. 32 535-539. [Pg.122]

Gray D, Shepherd H, Daar A, Oliver DO, Morris PJ. Oral versus intravenous high-dose steroid treatment of renal allograft rejection. The big shot or not Lancet 1978 l(8056) 117-8. [Pg.59]

Vascular cells play a pivotal role in inflammatory renal disease, renal allograft rejection, hypertension, and diabetic nephropathy. However, endothelial and smooth muscle cells are relatively resistant to gene transfer. The only vector that has been reported to... [Pg.172]

Thistlewaite, J., Gaber, A., Haag, B. et al. (1987). OKT3 treatment of steroid resistant renal allograft rejection. Transplantation 43, 176-184. [Pg.405]

Zenapax Daclizumab Hoffman-La Roche 12/1997 Prophylaxis of acute renal allograft rejection SP2/0... [Pg.1426]

Although FTY720 failed to improve efficacy for preventing renal allograft rejection in Phase III clinical studies (174), a different purpose has been found for its potential use. Phase III clinical trials are underway to examine the use of FTY720 for... [Pg.1774]

Woodle ES, Xu D, Zivin RA, Auger J, Charette J, O Laughlin R, Peace D, Jollife LK, Haverty T, Bluestone JA, Thistleth-waite JR Jr. (1999) Phase 1 trial of a humanized, Fc receptor nonbinding OKT3 antibody, huOKT3gammal(Ala-Ala) in the treatment of acute renal allograft rejection. Transplantation 68 608-616. [Pg.564]

Althongh snggested in one report, G-CSF does not appear to increase the risk of renal allograft rejection (SEDA-20, 337). [Pg.1546]

Several anti-human T cell monoclonal antibodies have undergone preliminary trials in the treatment of renal allograft rejection. Most of these monoclonal antibodies were not effective than muromonab (1). T10B9, an antihuman pan-T lymphocyte monoclonal antibody, had similar efficacy but caused less fever, severe infection, respiratory, gastrointestinal, or neurological sjmptoms than muromonab (SEDA-22, 409). Other monoclonal antibodies, such as chimeric anti-CD7 and murine anti-ICAM-1 (CD54 enhmomab), were devoid of adverse effects or produced only minimal and transient adverse effects (SED-13,1134). [Pg.2381]

Abciximab Prevention ot ischemic cardiac complications during percutaneous coronary interventions short-term prevention ot myocardial infarction Atelimomab Treatment ot sepsis Alemtuzumab Chronic lymphocytic leukemia Apolizumab Chronic lymphocytic leukemia Basiliximab Prevention ot acute renal allograft rejection Clenoliximab Rheumatoid arthritis Daclizumab Prevention ot acute renal allograft rejection Edrecolomab Adjuvant therapy tor cancer after colorectal surgery... [Pg.2381]

Inolimomab Prevention ot graft rejection Keliximab Rheumatoid arthritis Muromonab Prevention ot acute renal allograft rejection Natalizumab Acute relapse in multiple sclerosis Crohn s disease... [Pg.2381]

Gaughan WJ, Francos BB, Dunn SR, Francos GC, Burke JF. A retrospective analysis of the effect of indo-methacin on adverse reactions to orthoclone OKT3 in the therapy of acute renal allograft rejection. Am J Kidney Dis 1994 24(3) 486-90. [Pg.2400]

Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...